Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Align

Mass-Market B. infantis 35624 (P&G)

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

3 human trials, about 80 studies, ~5,000 participants (35624 strain across the trial program). The written rationale for this grade is still being prepared.

FDA
Consumer brand testing
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Single-strain product; the strongest evidence is narrow (abdominal pain and global IBS symptoms), and independent meta-analysis did not confirm benefit for bloating, gas or urgency despite consumer marketing. Effects are individual and often transient, and responders are hard to predict in advance. It is a consumer supplement, not a pharmaceutical-grade product, and is not a substitute for evaluation of IBS-type symptoms, which can overlap with conditions needing medical work-up. Anyone who is immunocompromised, pregnant, or managing a child's or adolescent's persistent GI symptoms, or whose symptoms include weight loss, bleeding, fever or night pain, should consult a qualified healthcare provider before starting or relying on any probiotic rather than self-treating.

Align is Procter & Gamble's mass-market probiotic built on the Bifidobacterium 35624 strain, discovered in Cork, Ireland by the Alimentary Pharmabiotic Centre lineage (later Alimentary Health / PrecisionBiotics) and licensed to P&G in 2005. The strain carries genuine single-strain IBS evidence for abdominal pain and global symptom relief, anchored by O'Mahony 2005 and the P&G-sponsored Whorwell 2006 trial, and reaffirmed by an independent 2026 strain-specific meta-analysis. The honest boundary of that evidence matters: the same independent meta-analysis found the strain does not clearly help bloating, gas or urgency, the very symptoms the brand foregrounds, and P&G settled a long-running U.S. class action over its broader 'digestive health' and 'clinically proven' marketing. Align therefore illustrates a real pattern, legitimate strain science surviving into the pharmacy aisle, alongside a real gap between narrow trial support and broad consumer positioning.

The mass-market home of the strongest IBS strain. Genuine evidence in a pharmacy product.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • IBS-associated abdominal pain and discomfort (best-supported single-strain use)
  • Global IBS symptom relief in responders
  • Daily digestive support (marketed use; weaker guideline support)

What people get wrong

  • Often saidAlign is just marketing with no real science behind it

    ActuallyThe 35624 strain has legitimate single-strain IBS trial evidence: O'Mahony 2005 (Gastroenterology) and Whorwell 2006 (Am J Gastroenterol) both showed abdominal-pain and global-symptom benefit versus placebo, and an independent 2026 meta-analysis (J Clin Med) reaffirmed it. The strain science is real; the open question is who responds.

  • Often saidAlign is clinically proven to fix bloating and gas

    ActuallyThis is a P&G brand emphasis, not a settled finding. The independent 2026 strain-specific meta-analysis (J Clin Med) found 35624's effect on bloating, gas, urgency and incomplete evacuation INSUFFICIENT, even while it confirmed benefit for abdominal pain. P&G also settled a U.S. class action (final approval 2018) over broader 'digestive health' and 'clinically proven' advertising and agreed to restrict certain claims, while denying wrongdoing.

  • Often saidEvery major gastroenterology body recommends Align for IBS

    ActuallyGuidelines diverge and several are cautious. The 2021 ACG guideline suggests AGAINST probiotics for global IBS symptoms (conditional, very-low evidence); the 2020 AGA guideline recommends probiotics for IBS only inside a clinical trial. BSG 2021 is more favorable but still rates the evidence weak. No major guideline singles out 35624 as a preferred strain.

  • Often saidAlign contains Bifidobacterium infantis

    ActuallyThe strain was reclassified from B. infantis to B. longum subsp. longum 35624 after whole-genome phylogenetic analysis (PLoS One 2016) showed the earlier name rested on partial 16S rRNA classification. The organism and its studied effects are unchanged; only the taxonomic label was corrected.

Who profits, and who pushes back

  • Gastroenterologists

    Promotes itClinical

    Recommend Align for IBS because of the 35624 strain evidence, despite its mass-market positioning.

  • Procter & Gamble

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itParent company

    Markets 35624 at scale; genuine strain evidence inside a consumer brand.

  • American College of Gastroenterology (2021 IBS Clinical Guideline authors, incl. Brian E. Lacy et al.)

    Pushes backPeer-reviewed U.S. specialty-society guideline

    The guideline states: 'We suggest against probiotics for the treatment of global IBS symptoms,' a conditional recommendation supported by a very low quality of evidence, citing small studies and the multiplicity of strains and products.

  • American Gastroenterological Association (2020 Probiotics Clinical Practice Guideline)

    Pushes backPeer-reviewed U.S. specialty-society guideline

    The AGA concluded there is insufficient evidence to recommend probiotics for IBS and suggested their use only in the context of a clinical trial, noting patients may reasonably consider stopping probiotics given cost and limited evidence of benefit.

  • Independent 2026 strain-specific meta-analysis (J Clin Med 15:1152; self-funded, no COI)

    Pushes backNon-industry systematic review with meta-analysis

    Pooling the 35624 trials, the authors found the strain reduces abdominal pain, straining and general IBS symptoms, but reported its effect on bloating, urgency, incomplete evacuation and gas passage to be insufficient, a boundary that does not match the brand's bloating-and-gas emphasis.

Where the research comes from

Most of the published research on this comes from one place. 60% of it is from USA. Findings that no unrelated group has reproduced are weaker than the study count makes them look.

Share of published research by country of origin.
PlaceShare of published research
USA60%
Other40%

Research published from: USA, Global.

How we got here

The 35624 strain was isolated from human gut tissue in Cork, Ireland, out of the University College Cork and Alimentary Pharmabiotic Centre research lineage that clinicians Fergus Shanahan and Eamonn Quigley helped anchor, and commercialized through the UCC spin-out Alimentary Health, founded 1999 (later PrecisionBiotics, acquired by Novozymes in 2020). This is an Irish-origin science story, not an American one: the pivotal early trials, O'Mahony 2005 and Whorwell 2006, ran through Cork and Manchester investigators before any consumer brand existed. Procter & Gamble, a consumer-products company better known for detergents and razors, licensed the strain in 2005, branded it Bifantis, and launched Align nationally in the U.S. in 2009 and in Canada in 2012. The arc typifies a recurring industry move: a large consumer firm acquiring genuine strain science and distributing it at scale, with the underlying evidence intact but the marketing pitched to wellness rather than to the specific IBS-pain claim the trials actually support.

  1. 2005O'Mahony trial (Gastroenterology, n=77) shows 35624 cuts IBS symptoms and normalizes an abnormal IL-10/IL-12 cytokine ratio
  2. 2005Alimentary Health (Cork) licenses B. infantis 35624 to Procter & Gamble
  3. 2006P&G-sponsored Whorwell trial (Am J Gastroenterol, n=362) finds the 1x10^8 CFU dose superior to placebo for abdominal pain and composite score
  4. 2009P&G launches Align nationally in the United States; Rikos class action filed the same era over marketing claims
  5. 2012Align launches in Canada
  6. 2016Whole-genome phylogenetics (PLoS One) reclassifies the strain from B. infantis to B. longum subsp. longum 35624 and describes its eps624 exopolysaccharide
  7. 2018U.S. District Court (S.D. Ohio) grants final approval to the ~$30M Rikos v. P&G Align class-action settlement; P&G denies wrongdoing but agrees to restrict certain 'clinically proven' claims
  8. 2020AGA guideline recommends probiotics for IBS only within a clinical trial; PrecisionBiotics acquired by Novozymes
  9. 2021ACG guideline suggests AGAINST probiotics for global IBS symptoms (conditional, very-low evidence)
  10. 2026Independent, self-funded strain-specific meta-analysis (J Clin Med) confirms 35624 helps abdominal pain and general IBS symptoms but not bloating, gas or urgency

At a glance

Strain
B. infantis 35624
Owner
Procter & Gamble
Best for
IBS
Evidence
Whorwell 2006 trial

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Align. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources